Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection

被引:331
作者
Haffner, Jeremie [1 ]
Lemaitre, Laurent [2 ]
Puech, Philippe [2 ]
Haber, Georges-Pascal
Leroy, Xavier [3 ,4 ,5 ]
Jones, J. Stephen
Villers, Arnauld [1 ]
机构
[1] Univ Lille Nord France, Dept Urol, F-59000 Lille, France
[2] Univ Lille Nord France, Dept Radiol, F-59000 Lille, France
[3] Univ Lille Nord France, Dept Pathol, F-59000 Lille, France
[4] INSERM, U703, F-59120 Loos, France
[5] CHU Lille, F-59000 Lille, France
关键词
prostate neoplasms; biopsy; diagnosis; magnetic resonance imaging; prognosis; CONTRAST-ENHANCED MRI; GUIDED BIOPSY; ZONE; DIAGNOSIS; ANTIGEN; VOLUME; TIME;
D O I
10.1111/j.1464-410X.2011.10112.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To compare magnetic resonance imaging (MRI)-targeted biopsies with extended systematic biopsies for the detection of significant prostate cancer. METHODS In all, 555 consecutive patients with suspicion of prostate cancer had pre-biopsy dynamic contrast-enhanced 1.5-tesla (T) MRI with pelvic coil, 10-12 transrectal ultrasound-guided extended systematic biopsies plus two targeted biopsies at any MRI area suspicious for malignancy. Significant prostate cancer was defined as >5 mm total cancer length and/or any Gleason pattern >3. Cancer length and grade at biopsy were reported and located on a 24-sector map. RESULTS Median (range) prostate-specific antigen (PSA) was 6.75 (0.18-100) ng/mL. MRI was positive in 351 (63%) patients and, overall, 302 (54%) had cancer at extended systematic biopsies and/or targeted biopsies. Of 302 cancers detected, 249 (82%) were significant prostate cancers and 53 (18%) were nonsignificant prostate cancers. Extended systematic biopsies did not detect 12 significant prostate cancers and targeted biopsies did not detect 13 significant prostate cancers. For significant prostate cancer detection, sensitivity, specificity and accuracy of targeted biopsies were 0.95, 1.0 and 0.98. The values for extended systematic biopsies were 0.95, 0.83, and 0.88. The detection accuracy of significant prostate cancer by targeted biopsies was higher than that by extended systematic biopsies (P < 0.001). Targeted biopsies also detected 16% more grade 4/5 cases and better quantified the cancer than extended systematic biopsies, with cancer length of 5.56 vs. 4.70 mm (P = 0.002). A targeted biopsies-only strategy without extended systematic biopsies would have necessitated a mean of 3.8 cores performed in only 63% of patients with positive MRI and avoided the potentially unnecessary diagnosis of 13% (53/302) of nonsignificant prostate cancers. CONCLUSIONS Strategy of targeted biopsies alone at prebiopsy MRI-suspicious areas is an attractive potential alternative to extended systematic biopsies for detection of significant prostate cancer. Further studies are necessary to validate the strategy of targeted biopsies alone.
引用
收藏
页码:E171 / E178
页数:8
相关论文
共 31 条
  • [1] Is it time to consider a role for MRI before prostate biopsy?
    Ahmed, Hashim U.
    Kirkham, Alex
    Arya, Manit
    Illing, Rowland
    Freeman, Alex
    Allen, Clare
    Emberton, Mark
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (04) : 197 - 206
  • [2] MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies
    Anastasiadis, Aristotelis G.
    Lichy, Matthias P.
    Nagele, Udo
    Kuczyk, Markus A.
    Merseburger, Axel S.
    Hennenlotter, Joerg
    Corvin, Stefan
    Sievert, Karl-Dietrich
    Claussen, Claus D.
    Stenzl, Arnulf
    Schlemmer, Heinz-Peter
    [J]. EUROPEAN UROLOGY, 2006, 50 (04) : 738 - 749
  • [3] Prostate saturation biopsy in the reevaluation of microfocal prostate cancer
    Boccon-Gibod, L. M.
    de Longehamps, N. Barry
    Toublanc, M.
    Boccon-Gibod, L. A.
    Ravery, V.
    [J]. JOURNAL OF UROLOGY, 2006, 176 (03) : 961 - 963
  • [4] Micro-focal prostate cancer: A comparison of biopsy and radical prostatectomy specimen features
    Boccon-Gibod, LM
    Dumonceau, O
    Toublanc, M
    Ravery, V
    Boccon-Gibod, LA
    [J]. EUROPEAN UROLOGY, 2005, 48 (06) : 895 - 899
  • [5] Transition Zone and Anterior Stromal Prostate Cancers: Zone of Origin and Intraprostatic Patterns of Spread at Histopathology
    Bouye, Sebastien
    Potiron, Eric
    Puech, Philippe
    Leroy, Xavier
    Lemaitre, Laurent
    Villers, Arnauld
    [J]. PROSTATE, 2009, 69 (01) : 105 - 113
  • [6] Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours
    Cirillo, S.
    Petracchini, M.
    Della Monica, P.
    Gallo, T.
    Tartaglia, V.
    Vestita, E.
    Ferrando, U.
    Regge, D.
    [J]. CLINICAL RADIOLOGY, 2008, 63 (08) : 871 - 879
  • [7] PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER
    EPSTEIN, JI
    WALSH, PC
    CARMICHAEL, M
    BRENDLER, CB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05): : 368 - 374
  • [8] Falzarano SM, 2010, UROLOGY, V76, P682, DOI 10.1016/j.urology.2009.11.067
  • [9] Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging
    Fuetterer, Jurgen J.
    Heijmink, Stijn W. T. P. J.
    Scheenen, Tom W. J.
    Veltman, Jeroen
    Huisman, Henkjan J.
    Vos, Pieter
    Hulsbergen-Van de Kaa, Christina A.
    Witjes, J. Alfred
    Krabbe, Paul F. M.
    Heerschap, Arend
    Barentsz, Jelle O.
    [J]. RADIOLOGY, 2006, 241 (02) : 449 - 458
  • [10] Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria:: is it reasonable?
    Girouin, Nicolas
    Mege-Lechevallier, Florence
    Senes, Alejandro Tonina
    Bissery, Alvine
    Rabilloud, Muriel
    Marechal, Jean-Marie
    Colombel, Marc
    Lyonnet, Denis
    Rouviere, Olivier
    [J]. EUROPEAN RADIOLOGY, 2007, 17 (06) : 1498 - 1509